Valuation: Jade Biosciences, Inc.

Market Cap 124.36Cr 108.78Cr 100.33Cr 93Cr 175.83Cr 12TCr 178.79Cr 1.2TCr 470.77Cr 5.84TCr 466.93Cr 456.77Cr 20TCr P/E 2026 *
-8.05x
P/E 2027 * -8.13x
Enterprise Value 99Cr 87Cr 80Cr 74Cr 139.99Cr 9.44TCr 142.34Cr 954.41Cr 374.8Cr 4.65TCr 371.74Cr 363.65Cr 16TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.17%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Jade Biosciences, Inc.

1 day-6.81%
1 week-2.60%
Current month-5.72%
1 month+30.29%
3 months+17.10%
6 months+54.84%
Current year+35.77%
1 week 19.76
Extreme 19.76
23.36
1 month 15.16
Extreme 15.16
23.49
Current year 12.45
Extreme 12.45
28
1 year 6.67
Extreme 6.67
28
3 years 6.56
Extreme 6.565
28
5 years 6.56
Extreme 6.565
28
10 years 6.56
Extreme 6.565
28
Manager TitleAgeSince
Chief Executive Officer 50 28/04/2025
Director of Finance/CFO 38 14/07/2025
Chief Tech/Sci/R&D Officer - 01/10/2024
Director TitleAgeSince
Chairman 57 28/04/2025
Director/Board Member 39 28/04/2025
Director/Board Member 48 28/04/2025
Date Insider Type Main position Quantity % Market Cap.
25/06Free

Director

47,675 0.0966%
09/06Free

Director

34,843 0.0706%
09/06Free

Chairman

34,843 0.0706%
Change 5-day change 1-year change 3-year change Capi.($)
-6.81%-2.60%+113.34% - 124.36Cr
+0.58%+2.06%+3.90%+10.40% 5.07TCr
-2.22%-1.25%+391.53%+591.38% 3.97TCr
-0.54%+0.39%+27.67%-3.89% 3.47TCr
-1.36%+0.35%+19.34%+58.83% 3.32TCr
+1.21%-4.58%+3.00%+37.03% 2.68TCr
-1.81%-1.48% - - 1.68TCr
+0.51%-3.47%+66.38%+125.61% 1.54TCr
+0.23%-0.58%+13.80%+19.56% 1.38TCr
-0.62%-3.09%+11.43%-29.93% 1.28TCr
Average -1.08%-1.01%+72.26%+101.12% 2.45TCr
Weighted average by Cap. -0.51%-0.24%+82.91%+126.14%

Financials

2026 *2027 *
Net sales - -
Net income -17Cr -15Cr -14Cr -13Cr -24Cr -1.65TCr -25Cr -166.97Cr -66Cr -813.78Cr -65Cr -64Cr -2.8TCr -19Cr -17Cr -15Cr -14Cr -27Cr -1.82TCr -27Cr -184.29Cr -72Cr -898.23Cr -72Cr -70Cr -3.09TCr
Net Debt -25Cr -22Cr -20Cr -19Cr -36Cr -2.42TCr -36Cr -244.39Cr -96Cr -1.19TCr -95Cr -93Cr -4.09TCr -30Cr -26Cr -24Cr -22Cr -42Cr -2.86TCr -43Cr -289.46Cr -113.67Cr -1.41TCr -112.74Cr -110.29Cr -4.85TCr
Logo Jade Biosciences, Inc.
Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
Employees
55
Date Price Change Volume
10/26/10 $20.95 -6.81% 14,13,164
09/26/09 $22.48 -0.22% 6,46,408
08/26/08 $22.53 +0.36% 8,78,516
07/26/07 $22.45 +5.40% 10,42,841
06/26/06 $21.30 -0.98% 10,56,288
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
20.95USD
Average target price
48.50USD
Spread / Average Target
+131.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JBIO Stock